Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant <i>Acinetobacter baumannii</i> Infections.

"Potential conflicts of interest. L.C. received honoraria for lectures from MICOM Srl and research grants from Gilead Italia. E.T. received honoraria for lectures from AbbVie, Gilead, MSD, and Jannsen; participated in advisory boards for Jannsen and Gilead Science; and received a research grant from Gilead Sciences. M.I. received honoraria for lectures from Biogen Italia, AIM Educational, andMICOM srl and research grants from Gilead Italia and Roche; M.I. also participated in an advisory board for BD Biosciences. M.A. received funding for participation in advisory boards, for the preparation of educational materials, for research and educational grants, for participation in speaker panels, and for support for travel to conferences from Gilead Sciences, Janssen-Cilag, Viiv Healthcare, Merck Sharp and Dohme, AbbVie, Angelini, Pfizer, GSK, Menarini, Astra Zeneca, and Moderna. L.S. received a research grant from Gilead and fees for lectures and expertise from Merck, Gilead, and Pfizer. The other authors declare no conflicts of interest."